Solidarity and trust in European Union health governance: three ways forward.

Trust and solidarity are centrally important to the functioning of healthcare systems, and for societal resilience and stability more broadly. The European Union is increasingly shaping governance and norms that affect trust and solidarity in health-a process that has intensified with the announcement of the 'European Health Union' in response to the COVID-19 pandemic. In this context, how can the EU ensure solidarity in health while generating public trust as a pre-condition for solidaristic institutions? We propose three strategies to reach this goal.

Ridesourcing platforms thrive on socio-economic inequality.

Limited available market share data seems to suggest that ridesourcing platforms benefit from, even thrive on, socio-economic inequality. We suspect that this is associated with high levels of socio-economic inequality allowing for cheap labour as well as increasing the share of travellers with a considerably above-average willingness to pay for travel time savings and comfort. We test the relation between inequality and system performance by means of an agent-based simulation model representing within-day and day-to-day supply-demand interaction in the ridesourcing market.

The path to a European Health Union.

The European Union has historically left health policy decisions to individual member states, cooperating only on issues like cross-border healthcare and medicine safety. However, the COVID-19 pandemic underscored the need for collective action across borders. In response, in October 2020, European Commission President Ursula von der Leyen called for the creation of a "European Health Union".

Establishing a health-based recommended occupational exposure limit for isoflurane using experimental animal data: a systematic review protocol.

Background: Isoflurane is used as an inhalation anesthetic in medical, paramedical, and veterinary practice. Epidemiological studies suggest an increased risk of miscarriages and malformations at birth related to maternal exposure to isoflurane and other inhalation anesthetics. However, these studies cannot be used to derive an occupational exposure level (OEL), because exposure was not determined quantitatively and other risk factors such as co-exposures to other inhalation anesthetics and other work-related factors may also have contributed to the observed adverse outcomes.